دورية أكاديمية
أعرض في EDS

Relationship of SARS-CoV-2-specific CD4 response to COVID-19 severity and impact of HIV-1 and tuberculosis coinfection.

التفاصيل البيبلوغرافية
العنوان: Relationship of SARS-CoV-2-specific CD4 response to COVID-19 severity and impact of HIV-1 and tuberculosis coinfection.
المؤلفون: Riou C; Wellcome Centre for Infectious Disease Research in Africa and Institute of Infectious Disease and Molecular Medicine.; Division of Medical Virology, Department of Pathology, and., du Bruyn E; Wellcome Centre for Infectious Disease Research in Africa and Institute of Infectious Disease and Molecular Medicine.; Department of Medicine, University of Cape Town, Cape Town, South Africa., Stek C; Wellcome Centre for Infectious Disease Research in Africa and Institute of Infectious Disease and Molecular Medicine.; Department of Medicine, University of Cape Town, Cape Town, South Africa.; Department of Infectious Diseases, Imperial College London, London, United Kingdom., Daroowala R; Wellcome Centre for Infectious Disease Research in Africa and Institute of Infectious Disease and Molecular Medicine.; Department of Medicine, University of Cape Town, Cape Town, South Africa.; Department of Infectious Diseases, Imperial College London, London, United Kingdom., Goliath RT; Wellcome Centre for Infectious Disease Research in Africa and Institute of Infectious Disease and Molecular Medicine., Abrahams F; Wellcome Centre for Infectious Disease Research in Africa and Institute of Infectious Disease and Molecular Medicine., Said-Hartley Q; Department of Radiology, University of Cape Town, Cape Town, South Africa., Allwood BW; Division of Pulmonology, Department of Medicine, Stellenbosch University and Tygerberg Hospital, Cape Town, South Africa., Hsiao NY; Division of Medical Virology, Department of Pathology, and.; National Health Laboratory Service, University of Cape Town and Groote Schuur Hospital, Cape Town, South Africa., Wilkinson KA; Wellcome Centre for Infectious Disease Research in Africa and Institute of Infectious Disease and Molecular Medicine.; Department of Medicine, University of Cape Town, Cape Town, South Africa.; The Francis Crick Institute, London, United Kingdom., Arlehamn CSL; Center for Infectious Disease, La Jolla Institute for Immunology, La Jolla, California, USA., Sette A; Center for Infectious Disease, La Jolla Institute for Immunology, La Jolla, California, USA.; Department of Medicine, School of Medicine, University of California San Diego, La Jolla, California, USA., Wasserman S; Wellcome Centre for Infectious Disease Research in Africa and Institute of Infectious Disease and Molecular Medicine.; Department of Medicine, University of Cape Town, Cape Town, South Africa., Wilkinson RJ; Wellcome Centre for Infectious Disease Research in Africa and Institute of Infectious Disease and Molecular Medicine.; Department of Medicine, University of Cape Town, Cape Town, South Africa.; Department of Infectious Diseases, Imperial College London, London, United Kingdom.; The Francis Crick Institute, London, United Kingdom.
مؤلفون مشاركون: HIATUS consortium
المصدر: The Journal of clinical investigation [J Clin Invest] 2021 Jun 15; Vol. 131 (12).
نوع المنشور: Clinical Trial; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: American Society for Clinical Investigation Country of Publication: United States NLM ID: 7802877 Publication Model: Print Cited Medium: Internet ISSN: 1558-8238 (Electronic) Linking ISSN: 00219738 NLM ISO Abbreviation: J Clin Invest Subsets: MEDLINE
أسماء مطبوعة: Publication: 1999- : Ann Arbor, MI : American Society for Clinical Investigation
Original Publication: New Haven [etc.] American Society for Clinical Investigation.
مواضيع طبية MeSH: CD4-Positive T-Lymphocytes/*immunology , COVID-19/*immunology , Coinfection/*immunology , HIV-1/*immunology , Mycobacterium tuberculosis/*immunology , SARS-CoV-2/*immunology , Tuberculosis/*immunology, Adult ; Aged ; CD4-Positive T-Lymphocytes/pathology ; COVID-19/pathology ; Coinfection/pathology ; Female ; Humans ; Male ; Middle Aged ; Severity of Illness Index ; Tuberculosis/pathology
مستخلص: T cells are involved in control of coronavirus disease 2019 (COVID-19), but limited knowledge is available on the relationship between antigen-specific T cell response and disease severity. Here, we used flow cytometry to assess the magnitude, function, and phenotype of SARS coronavirus 2-specific (SARS-CoV-2-specific) CD4+ T cells in 95 hospitalized COVID-19 patients, 38 of them being HIV-1 and/or tuberculosis (TB) coinfected, and 38 non-COVID-19 patients. We showed that SARS-CoV-2-specific CD4+ T cell attributes, rather than magnitude, were associated with disease severity, with severe disease being characterized by poor polyfunctional potential, reduced proliferation capacity, and enhanced HLA-DR expression. Moreover, HIV-1 and TB coinfection skewed the SARS-CoV-2 T cell response. HIV-1-mediated CD4+ T cell depletion associated with suboptimal T cell and humoral immune responses to SARS-CoV-2, and a decrease in the polyfunctional capacity of SARS-CoV-2-specific CD4+ T cells was observed in COVID-19 patients with active TB. Our results also revealed that COVID-19 patients displayed reduced frequency of Mycobacterium tuberculosis-specific CD4+ T cells, with possible implications for TB disease progression. These results corroborate the important role of SARS-CoV-2-specific T cells in COVID-19 pathogenesis and support the concept of altered T cell functions in patients with severe disease.
References: Science. 2020 Oct 2;370(6512):89-94. (PMID: 32753554)
Nat Med. 2020 Oct;26(10):1623-1635. (PMID: 32807934)
Int J Infect Dis. 2021 Dec;113 Suppl 1:S82-S87. (PMID: 33713816)
J Immunol Methods. 2004 Aug;291(1-2):185-95. (PMID: 15345316)
Am J Emerg Med. 2021 Jul;45:638-639. (PMID: 33246860)
Eur Respir J. 2020 Jul 30;56(1):. (PMID: 32482787)
Int J Infect Dis. 2021 Jan;102:163-169. (PMID: 33115677)
N Engl J Med. 2021 Feb 25;384(8):693-704. (PMID: 32678530)
PLoS Pathog. 2016 Jul 13;12(7):e1005760. (PMID: 27409590)
Nature. 2020 Aug;584(7821):457-462. (PMID: 32668444)
J Med Virol. 2021 Mar;93(3):1796-1804. (PMID: 32975842)
Eur Respir J. 2022 Jan 13;59(1):. (PMID: 34140294)
Sci Immunol. 2020 Jul 17;5(49):. (PMID: 32680954)
Cell. 2020 Oct 1;183(1):158-168.e14. (PMID: 32979941)
J Clin Microbiol. 2020 Sep 22;58(10):. (PMID: 32747400)
Curr Opin HIV AIDS. 2021 Jan;16(1):63-73. (PMID: 33186229)
Immunol Rev. 2013 Jul;254(1):326-42. (PMID: 23772629)
Nat Med. 2020 Jun;26(6):842-844. (PMID: 32398875)
Cell. 2020 Jun 25;181(7):1489-1501.e15. (PMID: 32473127)
Nat Rev Dis Primers. 2015 Oct 01;1:15035. (PMID: 27188527)
Int J Infect Dis. 2020 Jul;96:148-150. (PMID: 32335339)
Lancet Glob Health. 2020 Aug;8(8):e1003-e1017. (PMID: 32553130)
Cell. 2020 Nov 12;183(4):996-1012.e19. (PMID: 33010815)
Am J Respir Crit Care Med. 2021 Jun 15;203(12):1556-1565. (PMID: 33406011)
J Acquir Immune Defic Syndr. 2016 Feb 1;71(2):189-95. (PMID: 26361176)
Lancet HIV. 2021 Jan;8(1):e24-e32. (PMID: 33316211)
Lancet Infect Dis. 2020 Dec;20(12):1390-1400. (PMID: 32979318)
JCI Insight. 2020 Oct 15;5(20):. (PMID: 32937615)
Cell. 2020 Nov 25;183(5):1340-1353.e16. (PMID: 33096020)
Clin Infect Dis. 2004 Jun 15;38(12):e123-5. (PMID: 15227635)
Sci Immunol. 2020 Jun 26;5(48):. (PMID: 32591408)
Nat Rev Immunol. 2008 Apr;8(4):247-58. (PMID: 18323851)
Nat Rev Immunol. 2020 Sep;20(9):529-536. (PMID: 32728222)
Eur Respir J. 2020 Jul 9;56(1):. (PMID: 32457198)
Cell Mol Immunol. 2021 Apr;18(4):936-944. (PMID: 33139905)
Front Immunol. 2017 Aug 10;8:968. (PMID: 28848561)
Clin Transl Immunology. 2020 Sep 28;9(9):e1176. (PMID: 33005414)
Proc Natl Acad Sci U S A. 2018 Jan 30;115(5):E964-E973. (PMID: 29339504)
Front Immunol. 2017 Jan 23;8:19. (PMID: 28167943)
Pulmonology. 2021 Mar-Apr;27(2):151-165. (PMID: 33547029)
Science. 2020 Sep 4;369(6508):. (PMID: 32669297)
J Assoc Physicians India. 2020 Dec;68(12):69-72. (PMID: 33247647)
Eur Respir J. 2020 Nov 19;56(5):. (PMID: 33093125)
Nature. 2020 Nov;587(7833):270-274. (PMID: 32726801)
Clin Infect Dis. 2014 Feb;58(3):e44-100. (PMID: 24311479)
Nat Rev Immunol. 2020 Nov;20(11):709-713. (PMID: 33024281)
J Clin Invest. 2020 Dec 1;130(12):6477-6489. (PMID: 32833687)
Clin Infect Dis. 2021 Oct 5;73(7):e2095-e2106. (PMID: 33095853)
Clin Transl Immunology. 2020 Dec 23;9(12):e1217. (PMID: 33376594)
EMBO J. 2020 Dec 15;39(24):e105896. (PMID: 33140861)
J Clin Invest. 2020 Nov 2;130(11):6141-6150. (PMID: 32764200)
Lancet. 2020 Feb 15;395(10223):497-506. (PMID: 31986264)
Cell Rep Med. 2020 Sep 22;1(6):100081. (PMID: 32839763)
Clin Infect Dis. 2021 Oct 5;73(7):e2005-e2015. (PMID: 32860699)
Nat Rev Immunol. 2020 Aug;20(8):457-458. (PMID: 32636479)
Immunity. 2020 Oct 13;53(4):864-877.e5. (PMID: 32791036)
Cell Mol Immunol. 2020 May;17(5):541-543. (PMID: 32203186)
Medicine (Baltimore). 2020 Sep 04;99(36):e21803. (PMID: 32899009)
Front Cell Infect Microbiol. 2020 Jun 05;10:318. (PMID: 32582575)
BMC Infect Dis. 2020 Oct 9;20(1):744. (PMID: 33036570)
Nat Immunol. 2020 Nov;21(11):1336-1345. (PMID: 32887977)
Clin Chem. 2020 Aug 1;66(8):1104-1106. (PMID: 32484887)
Eur J Immunol. 2020 Dec;50(12):1998-2012. (PMID: 33073359)
PLoS One. 2020 Nov 17;15(11):e0241955. (PMID: 33201896)
معلومات مُعتمدة: FC001218 United Kingdom WT_ Wellcome Trust; 203135 United Kingdom WT_ Wellcome Trust; FC001218 United Kingdom ARC_ Arthritis Research UK; R21 AI148027 United States AI NIAID NIH HHS; 104803 United Kingdom WT_ Wellcome Trust; FC001218 United Kingdom MRC_ Medical Research Council; United Kingdom WT_ Wellcome Trust; K43 TW011421 United States TW FIC NIH HHS; FC001218 United Kingdom CRUK_ Cancer Research UK; 222574 United Kingdom WT_ Wellcome Trust
فهرسة مساهمة: Keywords: AIDS/HIV; COVID-19; Cellular immune response; T cells; Tuberculosis
تواريخ الأحداث: Date Created: 20210504 Date Completed: 20210628 Latest Revision: 20231107
رمز التحديث: 20240829
مُعرف محوري في PubMed: PMC8203446
DOI: 10.1172/JCI149125
PMID: 33945513
قاعدة البيانات: MEDLINE
الوصف
تدمد:1558-8238
DOI:10.1172/JCI149125